Impacts of Oxidative Stress and Anti-Oxidants on the Development, Pathogenesis, and Therapy of Sickle Cell Disease: A Comprehensive Review

The open-label, phase IIa, dose-finding ALICE study was conducted at six hospitals in Spain and enrolled patients aged 18 years or older with newly diagnosed acute myeloid leukemia not eligible for intensive chemotherapy and an ECOG performance status of 0–2.
[Lancet Haematology]